歌礼制药减重药物ASC47联合用药显著优于单药疗法

财中社2024-12-19

财中社12月19日电歌礼制药-B（01672）发布自愿性公告，宣布其治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果。在一项饮食诱导肥胖小鼠模型的研究中，ASC47低剂量联合用药使体重下降36.2%，而司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。此外，低剂量ASC47联合司美格鲁肽疗法使肥胖小鼠的肌肉总量占总体重...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2492719347?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-12-19 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492719347","market":"us","top_or_hot":-1,"title":"歌礼制药减重药物ASC47联合用药显著优于单药疗法","media":"财中社","content":"<html><body><div>\n<p>财中社12月19日电歌礼制药-B（01672）发布自愿性公告，宣布其治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果。在一项饮食诱导肥胖小鼠模型的研究中，ASC47低剂量联合用药使体重下降36.2%，而司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。此外，低剂量ASC47联合司美格鲁肽疗法使肥胖小鼠的肌肉总量占总体重...</p>\n<a href=\"http://finance.eastmoney.com/a/202412193272970722.html\">网页链接</a>\n</div>\n</body></html>","source":"stock_eastmoney","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>歌礼制药减重药物ASC47联合用药显著优于单药疗法</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n歌礼制药减重药物ASC47联合用药显著优于单药疗法\n</h2>\n<h4 class=\"meta\">\n\n\n2024-12-19 09:43 北京时间   <a href=\"http://finance.eastmoney.com/a/202412193272970722.html\"><strong>财中社</strong></a>\n</h4>\n</header>\n<article>\n<div>\n<p>财中社12月19日电歌礼制药-B（01672）发布自愿性公告，宣布其治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果。在一项饮食诱导肥胖小鼠模型的研究中，ASC47低剂量联合用药使体重下降36.2%，而司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。此外，低剂量ASC47联合司美格鲁肽疗法使肥胖小鼠的肌肉总量占总体重...</p>\n<a href=\"http://finance.eastmoney.com/a/202412193272970722.html\">网页链接</a>\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://finance.eastmoney.com/a/202412193272970722.html","article_id":"2492719347","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492719347","pubTimestamp":1734572616,"columns":[],"sourceInfo":{"source_id":"stock_eastmoney","name":"东方财富"},"weMediaInfo":null,"summary":"财中社12月19日电歌礼制药-B（01672）发布自愿性公告，宣布其治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果。在一项饮食诱导肥胖小鼠模型的研究中，ASC47低剂量联合用药使体重下降36.2%，而司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。","collect":0,"end_time":0,"defaultTopTitle":"eastmoney.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","BK1191":"制药","BK1515":"抗疫概念","01477":"欧康维视生物-B","01672":"歌礼制药-B"},"translate_title":"Ascletis Pharmaceuticals' weight loss drug ASC47 combination is significantly superior to monotherapy","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01477":1,"01672":1},"content_text":"财中社12月19日电歌礼制药-B（01672）发布自愿性公告，宣布其治疗肥胖症的减重不减肌候选药物ASC47与司美格鲁肽联合用药在临床前模型中显示出优于司美格鲁肽单药的减重效果。在一项饮食诱导肥胖小鼠模型的研究中，ASC47低剂量联合用药使体重下降36.2%，而司美格鲁肽单药使体重下降23.1%，联合用药比单药多减重56.7%。此外，低剂量ASC47联合司美格鲁肽疗法使肥胖小鼠的肌肉总量占总体重比例与健康非肥胖小鼠相似，显示出健康减重的潜力。　　根据体表面积换算，ASC47低剂量1（ASC47，3mg/kg，皮下注射，每四周一次）的人体等效剂量预估约为20mg。目前在澳大利亚进行的低密度脂蛋白胆固醇偏高受试者I期单剂量递增研究中，ASC47皮下注射的半衰期为21天，且显示出良好的耐受性，当前剂量已递增至90mg，未出现严重不良事件。更高剂量的研究仍在进行中，ASC47联合司美格鲁肽在降低空腹血糖、胆固醇和LDL-C方面均显示出统计学显著性降低。（文章来源：财中社）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.31.5","shortVersion":"4.31.5","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492719347"}